Superhero Drugs: Why Rare DNA Is Worth Billions

What’s good for patients is also good for business. The painkiller market alone is worth $18 billion a year. The drug industry is pressing ahead with research into genetic irregularities. The FDA is expected to approve a cholesterol-lowering treatment from Sanofi and Regeneron Pharmaceuticals based on the rare gene mutation of an aerobics instructor with astoundingly low cholesterol levels. Bloomberg's Caroline Chen has more on "Bloomberg Markets." (Source: Bloomberg)

Full Show: Bloomberg Daybreak: Americas (08/08)
31:32 - Bloomberg Daybreak: Americas hosted by David Westin Alix Steel. Guests include Kit Juckes, global strategist at Societe Generale, Ian Shepherdson, chief economist at Pantheon Macroeconomics, and Krishna Memani, chief investment officer at OppenheimerFunds. (Source: Bloomberg)
  • Bloomberg Markets: The Trump Economy 8/7/17
  • Full Show: Surveillance (08/04)
  • Merck KGaA CFO on Sales Forecast Cut, China Competition